AbCellera Biologics Inc. (ABCL) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Vancouver, BC, Canada. The current CEO is Carl Hansen.
ABCL has IPO date of 2020-12-11, 596 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $1.14B.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
